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Quality Improvement Program (NSQIP) database. Multi-
variable logistic regression analysis was performed to iden-
tify preoperative factors associated with 30-day mortality
and graft failure.
Results: Of the 493 patients who underwent AFB, 89
(18.05%) received a VG and 404 (81.95%) received a PG.
Thirty-day mortality rates for patients receiving VG and PG
were 2.25% and 6.19%, respectively (P  .14) and graft
failure rates were 6.74% and 2.97%, respectively (P  .08).
On multivariate analysis, there was no difference in 30-day
mortality (odds ratio (OR)0.53; 95% confidence interval
(CI) 0.11-2.56) or graft failure rate (OR2.38; 0.77-
7.34) for patients receiving VG or PG for AFB.Of the 1219
patients who underwent FFB, 251(20.59%) received a VG
and 968 (79.41%) received a PG. Thirty-day mortality rates
for patients receiving VG and PG were 1.99% and 1.03%,
respectively (P .21) and graft failure rates were 3.98% and
1.65%, respectively (P  .04). On multivariate analysis,
there was no difference in 30-day mortality (OR1.45;
CI 0.38-5.59) or graft failure rate (OR2.19; CI 0.94-
5.08) for patients receiving VG or PG for FFB.
Conclusions: Thirty-day mortality and graft failure
rate are independent of the type of conduit used in patients
undergoing extra-anatomic arterial bypass.
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Objectives: To compare early and follow-up results of
below-knee bypasses performed with a bioactive heparin-
treated ePTFE graft and with autologous saphenous vein
(ASV) in patients with critical limb ischemia in a multicen-
tric retrospective registry involving eight Italian and Amer-
ican vascular centres.
Methods: Over a nine year period, ending in 2010, a
heparin bonded prosthetic graft (Propaten Gore-Tex®,
W.L. Gore & Associates Inc, Flagstaff, AZ) was implanted
in 461 patients undergoing below-knee revascularization
for critical limb ischemia in seven Italian and one American
hospitals (HePTFE group). In the same period of time in
these eight centres 376 below-knee bypasses with ipsilateral
ASV in patients with critical limb ischemia were performed
(ASV group). Early (30 days) results were analyzed in
terms of graft patency, major amputation rates and mortal-
ity. Follow-up results were analyzed in terms of primary and
secondary graft patency, limb salvage and survival.
Results: Early graft thrombosis occurred in 52 patients
(33 in HePTFE group and 19 in ASV group); there were
26 early major amputations (19 in HePTFE group and 7 in
ASV group), with 30-day major amputation rates of 3.9%
and 1.9%, respectively (P .09).Mean duration of follow-up
was 27.1  22.4 months. Primary patency rate at 48
months was significantly better in ASV group (61.8%) than
in HePTFE group (38.5%; P  .001, log rank 19.1). The
rates of secondary patency at 48 months were 51.9% in
HePTFE group and 65.9% in ASV group (P .02, log rank
52); the corresponding values in terms of limb salvage and
amputation free-survival rates were 74.4% and 78.9% (P 
.3, log rank 0.9), and 52.9% and 54% (P .6, log rank 0.2),
respectively.
Conclusions: Heparin-bonded ePTFE graft provides
satisfactory early and mid-term results in patients undergo-
ing surgical treatment of critical limb ischemia. While au-
tologous saphenous vein maintains its superiority in terms
of primary and secondary patency, limb salvage rates are
comparable.
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Objectives: This article reports the early human results
of HELP technology in the prevention of major limb
amputation due to ischemia. In short-term aim was to
dilate pre-existing collateral channels and the long-term
aim was to stimulate remodelling and new collateral devel-
opment by increasing endothelial shear stress.
Methods: A pilot study consisted of 20 patients with
critical limb ischemia. These patients had no other option
but major amputation as determined by at least two vascu-
lar surgeons. The ischemic limb was isolated from the
systemic circulation by the use of an implantable, inflatable,
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